Indazole compounds as IRAK4 inhibitors

US10160753B2 · kind B2 · utility

Assignee

• Aurigene Discovery Technologies Limited · IN

Inventors

• Venkateshwar Rao Gummadi · Bengaluru, IN
• Susanta Samajdar · Savanuru, IN
• Ajay Gupta · Savanuru, IN

Key dates

• Filing date: Jan 7, 2015
• Grant date: Dec 25, 2018
• Expiry date: Jan 7, 2035

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07F9/11
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention provides indazole compounds of formula (I), which are therapeutically useful as kinase inhibitors, particularly IRAK4 inhibitors, wherein Z1, Z2, R1, R2, R3, ‘m’ and ‘n’ have the meanings given in the specification, and pharmaceutically acceptable salts or stereoisomers thereof that are useful in the treatment and prevention of diseases or disorders, in particular their use in diseases or disorders mediated by kinase enzyme, particularly IRAK4 enzyme. The present invention also provides pharmaceutical compositions comprising at least one of the compounds of the compound of formula (I) together with a pharmaceutically acceptable carrier, diluent or excipient.